![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/thomas_scriven.jpg?itok=Ktyzq1Nl&c=d7cdc0ea65c6d0e588a29bc8ab747512)
Thomas Scriven
Tom is a Strategic Consultant for Mandiant United Kingdom and Ireland, specialising in Security Operations and Threat Intelligence advisory services. He has significant experience as a trusted advisor to sensitive Government Departments, and has consulted for major Corporate entities, including in Critical National Infrastructure sectors, to undertake major cyber security assessments and implement complex cyber security transformation programmes. Tom has worked with large multinational companies to assess their security programmes, providing prioritised recommendations and roadmaps to enhance security posture and effectiveness.
![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/1541025271701.jpg?itok=IZ-6HTKB&c=5066c68cf6559f8f8b479c30f2c84817)
Oakley Cox
Oakley Cox is Director of Analysis at Darktrace, based at the Cambridge headquarters. He oversees the defense of critical infrastructure and industrial control systems, helping to ensure that Darktrace’s AI stays one step ahead of attackers. Oakley is GIAC certified in Response and Industrial Defense (GRID), and helps customers integrate Darktrace with both existing and new SOC and Incident Response teams. He also has a Doctorate (PhD) from the University of Oxford.
![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/lorena_lerner.png?itok=a9qerqOb&c=48cc3f6d5fe60ec79c36eec729722e96)
Lorena Lerner
Lorena Lerner Ph.D. is the Vice President of Research at Oncorus, where she is leading the efforts to engineer and develop novel oncolytic viral immunotherapies to treat solid tumors.
Lorena is an experienced cancer biologist with a proven track record of managing and advancing projects, from early discovery to clinical development. Most recently, Lorena served as Director of Biology at Quiet Therapeutics, where she was responsible for developing its proprietary nanotechnology platform, identifying potent immunotherapy target candidates, and optimizing vector design. Prior to Quiet, she served as Director of Target Discovery at Scholar Rock and held positions of increasing responsibilities at AVEO Oncology, where she pioneered and executed the development of AV-380, a cancer cachexia program targeting GDF15, from target identification, validation, and antibody discovery through preclinical development and out-licensing enterprises.
Lorena received an MSc in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed a post-doctoral research fellowship in Molecular and Cellular Biology with Professor James E. Darnell at Rockefeller University. Her academic training focused on the field of gene regulation and cancer molecular biology. Lorena is a co-inventor of numerous patents and high-impact, peer-reviewed manuscripts and abstracts.
![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/1620576875719.png?itok=8jQ3wxd4&c=294b9a6f2ad4a6ada27f79d28e7ff00d)